Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D'Cold is a prominent over-the-counter (OTC) brand of multi-symptom cold and flu medication, primarily marketed in India. Originally developed by Paras Pharmaceuticals and acquired by Reckitt Benckiser in 2010, the D'Cold product line includes various formulations such as D'Cold Total and D'Cold Next. These products typically combine an analgesic and antipyretic (paracetamol) with a nasal decongestant (phenylephrine) and either a stimulant (caffeine) or an antihistamine (chlorpheniramine maleate). It is indicated for the symptomatic relief of the common cold, including fever, body aches, headache, and nasal congestion. The brand is a staple in the Indian consumer healthcare market, leveraging a combination of well-established small molecule drugs to address upper respiratory symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D'Cold.